Join to View Full Profile
1110 Oak StAlyce Elmore Kraemer Cancer Care CenterWest Bend, WI 53095
Phone+1 262-334-8484
Fax+1 414-805-4944
Dr. Kamaraju is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Sailaja Kamaraju is a breast medical oncologist and a professor of medicine in the Division of Hematology-Oncology at Froedtert and the Medical College of Wisconsin in Milwaukee. She completed her medical education at Guntur Medical College. She pursued further training at Hennepin County Medical Center in Minneapolis, as well as a fellowship in hematology and medical oncology at the University of Minnesota. Her expertise includes breast medical oncology, with a research focus on cancer survivorship and breast cancer clinical trials. Dr. Kamaraju has contributed to several publications, including high-impact studies on breast cancer treatment and community-based participatory research. She has also served as a principal investigator in clinical trials focusing on breast cancer therapies and precision medicine.
Education & Training
University of MinnesotaFellowship, Hematology and Medical Oncology, 1999 - 2002
Hennepin HealthcareResidency, Internal Medicine, 1996 - 1999
Certifications & Licensure
WI State Medical License 2002 - 2027
American Board of Internal Medicine Medical Oncology
Clinical Trials
- Carboplatin and Paclitaxel or Oxaliplatin and Capecitabine With or Without Bevacizumab as First-Line Therapy in Treating Patients With Newly Diagnosed Stage II-IV or Recurrent Stage I Epithelial Ovarian or Fallopian Tube Cancer Start of enrollment: 2010 Oct 12
- Onapristone and Fulvestrant for ER+ HER2- Metastatic Breast Cancer After Endocrine Therapy and CDK4/6 Inhibitors (The SMILE Study) Start of enrollment: 2021 Oct 05
- A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer Start of enrollment: 2022 Mar 07
Roles: Principal Investigator, Contact
- Join now to see all
Publications & Presentations
PubMed
- Evaluation and management of incomplete ovarian function suppression in premenopausal breast cancer patients receiving anti-hormone therapy.Ruchi Patel, Elizabeth Weil, Sara Bugamelli, Emma Carroll, Kylie Steinke
Breast Cancer Research. 2025-08-18 - National trends in neoadjuvant systemic therapy utilization in patients with early-stage HER2-positive breast cancer from 2016-2021: The impact of the KATHERINE trial.Lauren N Cohen, Christine C Rogers, Jan Irene C Lloren, Sailaja Kamaraju, Lubna N Chaudhary
Breast Cancer Research and Treatment. 2025-08-01 - Breast Cancer Outcomes in Transgender and Gender-Diverse Patients in the National Cancer Database.Kelley Chan, Joseph H Cotler, Alexandra C Istl, Sailaja Kamaraju, Andrew E Petroll
JAMA Oncology. 2025-07-01
Press Mentions
BriaCell Presents Unprecedented Overall Survival Data in Metastatic Breast CancerDecember 11th, 2024- Context Therapeutics® to Present Clinical Data on ONA-XR in Breast Cancer at 2021 San Antonio Breast Cancer SymposiumNovember 19th, 2021
Context Therapeutics and Wisconsin Oncology Network (WON) to Evaluate Apristor Combination Therapy for Women with Advanced Breast CancerOctober 7th, 2019
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
